Hearings in January revealed that the release of negative results of a clinical trial
of ezetimibe had been delayed.
Not exact matches
Instead,
ezetimibe blocks dietary cholesterol absorption in the gut by inhibiting the NPC1L1 protein, perhaps approximating the effect
of having only one working copy
of the NPC1L1 gene.
The gene, called NPC1L1, is
of interest because it is the target
of the drug
ezetimibe, often prescribed to lower cholesterol.
ORLANDO, Fla. — Adding a pharmaceutical form
of the B vitamin niacin — but not the drug
ezetimibe — to a cholesterol - lowering statin drug appears to reduce artery plaque buildup in patients with coronary artery disease, according to much - anticipated results announced at a press conference November 15.
The results were from a study that was relatively small — only 208 patients — but provided a head - to - head comparison
of niacin and
ezetimibe, known by the brand name Zetia.
Among medications that lower cholesterol,
ezetimibe is not in the widely prescribed class
of drugs called statins, which stop the body from manufacturing its own cholesterol.
While
ezetimibe is known for its cholesterol - lowering effect, there is debate over whether it also reduces risk
of heart disease.
Stein E. Results
of phase I / II clinical trials with
ezetimibe, a novel selective cholesterol absorption inhibitor.
Ezetimibe: a selective inhibitor
of cholesterol absorption.
Statins block cholesterol made in the liver, while
ezetimibe blocks the absorption
of cholesterol in the gut.